T Cells Target APOBEC3 Proteins in Human Immunodeficiency Virus Type 1-Infected Humans and Simian Immunodeficiency Virus-Infected Indian Rhesus Macaques
Carregando...
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER SOC MICROBIOLOGY
Autores
CHAMPIAT, Stephane
GARRISON, Keith E.
RAPOSO, Rui Andre Saraiva
BURWITZ, Benjamin J.
REED, Jason
TANDON, Ravi
YORK, Vanessa A.
NEWMAN, Laura P.
NIMITYONGSKUL, Francesca A.
WILSON, Nancy A.
Citação
JOURNAL OF VIROLOGY, v.87, n.11, p.6073-6080, 2013
Resumo
APOBEC3 proteins mediate potent antiretroviral activity by hypermutating the retroviral genome during reverse transcription. To counteract APOBEC3 and gain a replicative advantage, lentiviruses such as human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) have evolved the Vif protein, which targets APOBEC3 proteins for proteasomal degradation. However, the proteasome plays a critical role in the generation of T cell peptide epitopes. Whether Vif-mediated destruction of APOBEC3 proteins leads to the generation and presentation of APOBEC3-derived T cell epitopes on the surfaces of lentivirus-infected cells remains unknown. Here, using peptides derived from multiple Vif-sensitive APOBEC3 proteins, we identified APOBEC3-specific T cell responses in both HIV-1-infected patients and SIV-infected rhesus macaques. These results raise the possibility that these T cell responses may be part of the larger antiretroviral immune response.
Palavras-chave
Referências
- Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a
- Bennett MS, 2008, J INFECT DIS, V197, P390, DOI 10.1086/525281
- Berger G, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002221
- Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
- Chiu YL, 2008, ANNU REV IMMUNOL, V26, P317, DOI 10.1146/annurev.immunol.26.021607.090350
- Cullen BR, 2006, J VIROL, V80, P1067, DOI 10.1128/JVI.80.3.1067-1076.2006
- Dilernia DA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003429
- Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
- Guo F, 2006, J VIROL, V80, P11710, DOI 10.1128/JVI.01038-06
- Harris RS, 2012, J BIOL CHEM, V287, P40875, DOI 10.1074/jbc.R112.416925
- Hutchinson SL, 2003, J BIOL CHEM, V278, P24285, DOI 10.1074/jbc.M300633200
- Jaini R, 2010, NAT MED, V16, P799, DOI 10.1038/nm.2161
- Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718
- Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003
- Kawashima Y, 2009, NATURE, V458, P641, DOI 10.1038/nature07746
- Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19
- Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992
- Liu JY, 2009, NATURE, V457, P87, DOI 10.1038/nature07469
- Loffredo JT, 2007, J VIROL, V81, P2624, DOI 10.1128/JVI.01912-06
- Luo K, 2004, J VIROL, V78, P11841, DOI 10.1128/JVI.78.21.11841-11852.2004
- Malim MH, 2009, PHILOS T R SOC B, V364, P675, DOI 10.1098/rstb.2008.0185
- Matzinger P, 2007, NAT IMMUNOL, V8, P11, DOI 10.1038/ni0107-11
- Mbisa JL, 2010, J VIROL, V84, P5250, DOI 10.1128/JVI.02358-09
- Meiklejohn DA, 2004, J IMMUNOL METHODS, V288, P135, DOI 10.1016/j.jim.2004.03.006
- O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493
- Parmiani G, 2007, J IMMUNOL, V178, P1975
- Rowe HM, 2011, VIROLOGY, V411, P273, DOI 10.1016/j.virol.2010.12.007
- Sacha JB, 2007, J IMMUNOL, V178, P2746
- Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945
- Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00969
- Slingluff CL, 2003, J CLIN ONCOL, V21, P4016, DOI 10.1200/JCO.2003.10.005
- Strebel K, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-48
- Valentine LE, 2008, J VIROL, V82, P575, DOI 10.1128/JVI.00275-07
- Virgen CA, 2007, J VIROL, V81, P13932, DOI 10.1128/JVI.01760-07
- Wilson NA, 2009, J VIROL, V83, P6508, DOI 10.1128/JVI.00272-09
- Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818